GlaxoSmithKline (GSK.L) and CureVac (5CV.DE) said a study on macaque monkeys showed their jointly-developed mRNA COVID-19 vaccine candidate to be "strongly improved" in protecting against the virus compared with CureVac's first attempt.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,